A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer

Journal of Nuclear Medicine

Volumn 41, Issue 7, 2000, Pages 1177-1189

  Huebner, Ralf H ^a   Park, Kenneth C ^a   Shepherd, James E ^a   Schwimmer, Judy ^a   Czernin, Johannes ^a   Phelps, Michael E ^a   Gambhir, Sanjiv S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cancer; Colorectal; FDG PET; Meta analysis; Recurrent

Indexed keywords

ARTICLE; CALCULATION; CANCER DIAGNOSIS; CANCER RECURRENCE; CLINICAL TRIAL; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HUMAN; META ANALYSIS; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PRIORITY JOURNAL;

COLORECTAL NEOPLASMS; FLUORODEOXYGLUCOSE F18; HUMANS; LIVER NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; PELVIC NEOPLASMS; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0033925753     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Landis SH, Murray T, Bolden S, Wingo P. Cancer statistics. CA Cancer J Clin. 1998;48:6-29.
2. Flanagan FL, Dehdashti F, Ogunbiyi OA, Kodner IJ, Siegel BA. Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer. Ann Surg. 1998;227:319-323.
3. Valk PE, Abella-Columna E, Hasemann MK, et al. Whole body PET imaging with F-18 fluorodeoxyglucose in management of recurrent colorectal cancer. Arch Surg. 1999;134:503-511.
4. Ogunbiyi OA, Flanagan FL, Dehdashti F, et al. Detection of recurrent and metastatic colorectal cancer: comparison of positron emission tomography and computed tomography. Ann Surg Oncol. 1997;4:613-620.
5. Turk PS, Wanebo HJ. Resection of pelvic recurrences. In: Wanebo HJ, ed. Colorectal Cancer. St. Louis, MO: CV Mosby; 1993:443-463.
6. August DA, Otlow RT, Sugenberker PH. Clinical perspectives on human colorectal cancer metastases. Cancer Metastasis Rev. 1984;3:303-324.
7. Steele GJ, Bleday R, Mayer RJ, Lindblad A, Petrelli N, Weaver D. A prospective evaluation of hepatic resection for colorectal carcinoma metastases to the liver: gastrointestinal tumor study group protocol 6584. J Clin Oncol. 1991:1105-1112.
8. Saenz NC, Cady B, McDermott WVJ. Experience with colorectal carcinoma metastatic to the liver. Surg Clin North Am. 1989;69:359-368.
9. Hughes KS, Simon R, Songhorabody S. Resection of the liver for colorectal carcinoma metastases to the liver: a multi-institutional study of indications for resection. Surgery. 1988;103:278-288.
10. Nieweg OE. Potential applications of positron emission tomography in surgical oncology. Eur J Surg Oncol. 1994;20:415-424.
11. Strauss LG, Conti PS. The applications of PET in clinical oncology. J Nucl Med. 1991;32:623-650.
12. Wagner HNJ, Conti PS. Advances in medical imaging for cancer diagnosis and treatment. Cancer. 1991;67:1121-1128.
13. Conti PS, Lilien DL, Hawley K, Keppler J, Grafton ST, Bading JR. PET and 18-F-FDG in oncology: a clinical update. Nucl Med Biol. 1996;23:717-735.
14. Gambhir SS, Hoh CK, Phelps ME, Madar I, Maddahi J. Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma. J Nucl Med. 1996;37:1428-1436.
15. Gambhir SS, Shepherd JE, Shah BD, et al. Analytical decision model for the cost-effective management of solitary pulmonary nodules. J Clin Oncol. 1998;16: 2113-2125.
16. Valk PE, Pounds TR, Tesar RD, Hopkins DM, Haseman MK. Cost-effectiveness of PET imaging in clinical oncology. Nucl Med Biol. 1996;23:737-743.
17. Abdel-Nabi H, Doerr RJ, Lamonica DM, et al. Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings. Radiology. 1998;206:755-760.
18. Scott W, Shepherd J, Gambhir S. Cost-effectiveness of FDG-PET for staging non-small cell lung cancer: a decision analysis, Ann Thorac Surg. 1998;66:1876-1883.
19. Thacker SB. A quantitative approach to research integration. JAMA. 1988;259: 1685-1689.
20. Sacks HS, Berrier J, Reitman D. Meta-analysis of randomized controlled trials. N Engl J Med. 1987;316:450-455.
21. L'Abbe KA, Detsky AS, O'Rourke K. Meta-analysis in clinical research. Ann Intern Med. 1987;107:224-233.
22. Irwig L, Tosteson AN, Gatsonis C, et al. Guidelines for meta-analyses evaluating diagnostic tests. Ann Intern Med. 1994;120:667-676.
23. Irwig L, Macaskill P, Glasziou P, Fahey M. Meta-analytic methods for diagnostic test accuracy. J Clin Epidemiol. 1995;48:119-130.
24. Delbeke D, Vitola JV, Sandler MP, et al. Staging recurrent metastatic colorectal carcinoma with PET. J Nucl Med. 1997;38:1196-1201.
25. Keogan MT, Lowe VJ, Baker ME, McDermott VG, Lyerly HK, Coleman RE. Local recurrence of rectal cancer: evaluation of F-18 fluorodeoxyglucose PET imaging. Abdom Imaging. 1997;22:332-337.
26. 18F]fluorodeoxyglucose in identifying operable colorectal cancer metastases to the liver. Arch Surg. 1996;131:703-707.
27. Vitola JV, Delbeke D, Sandler MP, et al. Positron emission tomography to stage suspected metastatic colorectal carcinoma to the liver. Am J Surg. 1996;171: 21-26.
28. Schiepers C, Penninckx F, De Vadder N, et al. Contribution of PET in the diagnosis of recurrent colorectal cancer: comparison with conventional imaging. Eur J Surg Oncol. 1995;21:517-522.
29. 18F)fluorodeoxyglucose in recurrent colorectal cancer. Br J Surg. 1994;81:1666-1670.
30. Ruhlmann J, Schomburg A, Bender H, et al. Fluorodeoxyglucose whole-body positron emission tomography in colorectal cancer patients studied in routine daily practice. Dis Colon Rectum. 1997;40:1195-1204.
31. Flamen P, Stroobants S, Van Cutsem E, et al. Additional value of whole-body positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose in recurrent colorectal cancer. J Clin Oncol. 1999;17:894-901.
32. Gleeson S. Blue Cross and Blue Shield association initiatives in technology assessment. In: Dawkins HV, Gelijns AC, eds. Adopting New Medical Technology. Washington, DC: National Academy Press; 1994:96-100.
33. Lairson PD. Kaiser Permanente's new technology committee: coverage decision making in a group model health maintenance organization. In: Dawkins HV, Gelijns AC, eds. Adopting New Medical Technology. Washington DC: National Academy Press; 1994:101-108.
34. Buto KA. Decision making in the health care finance administration. In: Dawkins HV, Gelijns AC, eds. Adopting New Medical Technology. Washington DC: National Academy Press; 1994:87-95.
35. Galandiuk S, Wieand H, Moertel C, et al. Patterns of recurrence after curative resection of carcinoma of the colon and rectum. Surgery. 1992;174:27-32.
36. Olson RM, Perencevich NP, Malcolm AW, Chaffey JT, Wilson RE. Patterns of recurrence following curative resection of adenocarcinoma of the colon and rectum. Cancer. 1980;45:2969-2974.
37. Pilipshen S, Martin H, Stuart H, Quan Q, Sternberg S, Enker W. Patterns of pelvic recurrences following definitive resections of rectal cancer. Cancer. 1984;53:1354-1362.
38. Papatheofanis FJ. Strategies for reporting evidence-based clinical studies involving positron imaging. Clin Positron Imaging. 1998;1:175-184.
39. Ota T, Ito K, Tadokoro M, et al. Evaluation of the performance of a whole-body positron imaging system with attenuation correction. Radiat Med. 1995;13:121-128.
40. Bengel FM, Ziegler SI, Avril N, Weber W, Laubenbacher C, Schwaiger M. Whole-body positron emission tomography in clinical oncology: comparison between attenuation-corrected and uncorrected images. Eur J Nucl Med. 1997;24: 1091-1098.
41. Dahlbom M, Hoffman EJ, Hoh CK, et al. Whole-body positron emission tomography: part I. Methods and performance characteristics. J Nucl Med. 1992;33:1191-1199.
42. Littenberg B, Moses L. Estimating diagnostic accuracy from multiple conflicting reports. Med Decis Making. 1993;13:313-321.
43. Simel DL. Likelihood ratios with confidence: sample size estimation for diagnostic test studies. J Clin Epidemiol. 1991;44:763-70.
44. Freund J. Mathematical Statistics. 5th ed. Englewood Cliffs, NJ: Prentice Hall: 1992:477-480.